For that purpose, we performed different IC50 assays in our breast cancer cell lines that overexpress MEG8. We found that cells with increased MEG8 were more resistant to carboplatin and 5FU treatments in all the breast cancer cell lines used. This evidence concerns the gene MEG8 and breast carcinoma.